Related Experiment Video
Updated: Apr 1, 2026
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
Therapeutic effect of CNP on renal osteodystrophy by antagonizing the FGF-23/MAPK pathway
Peng Hu1, Bao Yu Huang1, Xun Xia1
1a Department of Pediatrics , The First Affiliated Hospital of Anhui Medical University , Hefei , People's Republic of China .
Abstract:
Renal osteodystrophy (ROD) is highly prevalent in chronic kidney disease (CKD). Because most patients with ROD are asymptomatic in the early stage and bone biopsy remains not a routine procedure in many clinical settings; therefore, several biochemical parameters may help to identify the existence of ROD. C-type natriuretic peptide (CNP) is considered as a positive regulator of bone formation. Both urinary excretion and renal expression of CNP are markedly up-regulated in the early stages of CKD, whereas they are still progressively declined accompanied by CKD progression, which invites speculation that the progressive decline of CNP may contribute, in part, to the pathogenesis of ROD. In addition, fibroblast growth factor (FGF)-23 is a bone-derived endocrine regulator of phosphate homeostasis. The elevation of serum FGF-23 has been recognized as a common feature in CKD to maintain normophosphatemia at the expense of declining 1,25-dihydroxyvitamin D values. Since the effects of CNP and FGF-23 on bone formation appear to oppose each other, it is reasonable to propose a direct interaction of their signaling pathways during the progression of ROD. CNP and FGF-23 act through a close or reciprocal pathway and are in agreement with recent studies demonstrating a down-regulatory role of the mitogen-activated protein kinase activity by CNP. The specific node may act at the level of RAF-1 through the activation of cyclic guanosine monophosphate-dependent protein kinases II.
Insights
Renal osteodystrophy (ROD) in chronic kidney disease (CKD) may be linked to declining C-type natriuretic peptide (CNP) levels. Fibroblast growth factor (FGF)-23 may interact with CNP, influencing bone health during CKD progression.
Area of Science:
- Nephrology
- Endocrinology
- Bone Biology
Background:
- Renal osteodystrophy (ROD) is common in chronic kidney disease (CKD), often presenting asymptomatically.
- Biochemical markers are crucial for diagnosing ROD due to the infrequent use of bone biopsies.
- C-type natriuretic peptide (CNP) promotes bone formation, with its levels initially rising then falling in CKD.
Purpose of the Study:
- To investigate the potential role of declining C-type natriuretic peptide (CNP) in the pathogenesis of ROD.
- To explore the interaction between CNP and fibroblast growth factor (FGF)-23 signaling pathways in CKD-related bone disease.
Main Methods:
- The study speculates on the interaction between CNP and FGF-23 based on their known roles in bone metabolism and CKD.
- It references existing research on the down-regulatory effects of CNP on mitogen-activated protein kinase activity.
Main Results:
- Urinary and renal CNP levels increase in early CKD but decrease as the disease progresses.
- Elevated serum FGF-23 is a hallmark of CKD, maintaining phosphate balance at the cost of vitamin D levels.
- CNP and FGF-23 signaling pathways may interact, potentially influencing ROD development.
Conclusions:
- Progressive decline of CNP may contribute to ROD pathogenesis in CKD.
- A reciprocal interaction between CNP and FGF-23 pathways is proposed, possibly mediated through RAF-1 and cyclic guanosine monophosphate-dependent protein kinases II.
- Understanding this interaction could offer new insights into managing bone complications in CKD.
More Related Videos
03:56Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:28Chronic Kidney Disease III: Interprofessional Care
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...